PMID- 32340373
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20240328
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Apr 23
TI  - Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs.
LID - 10.3390/molecules25081987 [doi]
LID - 1987
AB  - Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects 
      a large part of population and according to the World Health Organization (WHO) 
      the number of adults living with diabetes is expected to increase. Since type 2 
      diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 
      90-95%) and often the mono-target therapy fails in managing blood glucose levels 
      and the other comorbidities, this review focuses on the potential drugs acting on 
      multi-targets involved in the treatment of this type of diabetes. In particular, 
      the review considers the main systems directly involved in T2DM or involved in 
      diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as 
      on peroxisome proliferation activated receptors are considered. Inhibitors which 
      target either aldose reductase and tyrosine phosphatase 1B or sodium glucose 
      transporters 1 and 2 are taken into account. Moreover, with a view at the 
      multi-target approaches for T2DM some phytocomplexes are also discussed.
FAU - Artasensi, Angelica
AU  - Artasensi A
AD  - Dipartimento di Scienze Farmaceutiche, University Degli Studi di Milano, 20133 
      Milano, Italy.
FAU - Pedretti, Alessandro
AU  - Pedretti A
AUID- ORCID: 0000-0001-5916-2029
AD  - Dipartimento di Scienze Farmaceutiche, University Degli Studi di Milano, 20133 
      Milano, Italy.
FAU - Vistoli, Giulio
AU  - Vistoli G
AD  - Dipartimento di Scienze Farmaceutiche, University Degli Studi di Milano, 20133 
      Milano, Italy.
FAU - Fumagalli, Laura
AU  - Fumagalli L
AUID- ORCID: 0000-0003-1917-3000
AD  - Dipartimento di Scienze Farmaceutiche, University Degli Studi di Milano, 20133 
      Milano, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200423
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Ligands)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Biomarkers
MH  - Diabetes Mellitus, Type 2/drug therapy/*etiology/*metabolism
MH  - Disease Susceptibility
MH  - Drug Design
MH  - *Drug Discovery
MH  - Drug Evaluation, Preclinical
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Incretins/chemistry/pharmacology/therapeutic use
MH  - Ligands
MH  - Molecular Targeted Therapy
MH  - Structure-Activity Relationship
PMC - PMC7221535
OTO - NOTNLM
OT  - diabetes mellitus
OT  - multi-target compounds
OT  - multi-target drugs
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/29 06:00
MHDA- 2021/01/30 06:00
PMCR- 2020/04/23
CRDT- 2020/04/29 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/04/23 00:00 [pmc-release]
AID - molecules25081987 [pii]
AID - molecules-25-01987 [pii]
AID - 10.3390/molecules25081987 [doi]
PST - epublish
SO  - Molecules. 2020 Apr 23;25(8):1987. doi: 10.3390/molecules25081987.